Please login to the form below
UCB appoints Peter Theil head of non-clinical development
He joins the Belgium pharma company from Genentech
Peter Theil has joined UCB as vice president, head of non-clinical development for UCB's New Medicines research arm.
He joins the Belgium pharma company from Genentech, where he was head of early development, pharmacokinetic/pharmacodynamics sciences.
At UCB he will be part of New Medicine's leadership team and will be based in Braine, Belgium.
UCB said Theil's scientific knowledge, organisational and leadership skills would invaluable in continuing it unique emphasis and success in developing both small and large molecules.
Peter is the second new member of the New Medicines leadership team, following the recent appointment of Duncan McHale, who joined UCB as VP head of global exploratory development.
McHale moved to the company from AstraZeneca, where he was held the role of head of projects, VP personalised medicine and biomarkers.
Share
Related Hub content
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- THE EVOLVING ROLE OF PROCUREMENT?
- Origins' Solutions Offering Explained
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Alzheimer’s Association report highlights need to improve patient-physician communication
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- Eli Lilly announces 70% cut to US insulin prices while also capping out-of-pocket costs
- Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate
- Origins Insights Offering Explained
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
- THE EVOLVING ROLE OF PROCUREMENT?
- Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...
